Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | M552_K558del |
Impact List | deletion |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT M552_K558del results in the deletion of seven amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 552 to 558 (PMID: 16226710). M552_K558del has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT M552_K558del KIT mutant KIT exon11 KIT exon 11 del KIT M552_K558del |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727422_54727442del21 |
cDNA | c.1654_1674del21 |
Protein | p.M552_K558delMYEVQWK |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017008180 | chr4:g.54727434_54727454del21 | c.1654_1674del21 | p.Q552_E558delQWKVVEE | RefSeq | GRCh38/hg38 |
NM_001093772.1 | chr4:g.54727434_54727454del21 | c.1654_1674del21 | p.Q552_E558delQWKVVEE | RefSeq | GRCh38/hg38 |
XM_017008180.1 | chr4:g.54727434_54727454del21 | c.1654_1674del21 | p.Q552_E558delQWKVVEE | RefSeq | GRCh38/hg38 |
NM_001093772 | chr4:g.54727434_54727454del21 | c.1654_1674del21 | p.Q552_E558delQWKVVEE | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54727419_54727439del21 | c.1654_1674del21 | p.P552_W558delPMYEVQW | RefSeq | GRCh38/hg38 |
NM_001385292.1 | chr4:g.54727432_54727452del21 | c.1655_1675del21 | p.V552_E558delVQWKVVE | RefSeq | GRCh38/hg38 |
NM_001093772.2 | chr4:g.54727434_54727454del21 | c.1654_1674del21 | p.Q552_E558delQWKVVEE | RefSeq | GRCh38/hg38 |
XM_017008178 | chr4:g.54727422_54727442del21 | c.1654_1674del21 | p.M552_K558delMYEVQWK | RefSeq | GRCh38/hg38 |
XM_005265740.1 | chr4:g.54727419_54727439del21 | c.1654_1674del21 | p.P552_W558delPMYEVQW | RefSeq | GRCh38/hg38 |
XM_005265742 | chr4:g.54727432_54727452del21 | c.1655_1675del21 | p.V552_E558delVQWKVVE | RefSeq | GRCh38/hg38 |
XM_005265741 | chr4:g.54727419_54727439del21 | c.1654_1674del21 | p.P552_W558delPMYEVQW | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727422_54727442del21 | c.1654_1674del21 | p.M552_K558delMYEVQWK | RefSeq | GRCh38/hg38 |
NM_001385288.1 | chr4:g.54727432_54727452del21 | c.1655_1675del21 | p.V552_E558delVQWKVVE | RefSeq | GRCh38/hg38 |
XM_005265742.3 | chr4:g.54727432_54727452del21 | c.1655_1675del21 | p.V552_E558delVQWKVVE | RefSeq | GRCh38/hg38 |
XM_005265740 | chr4:g.54727419_54727439del21 | c.1654_1674del21 | p.P552_W558delPMYEVQW | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727422_54727442del21 | c.1654_1674del21 | p.M552_K558delMYEVQWK | RefSeq | GRCh38/hg38 |
NM_001385286.1 | chr4:g.54727434_54727454del21 | c.1654_1674del21 | p.Q552_E558delQWKVVEE | RefSeq | GRCh38/hg38 |
XM_017008179 | chr4:g.54727432_54727452del21 | c.1655_1675del21 | p.V552_E558delVQWKVVE | RefSeq | GRCh38/hg38 |
XM_005265741.1 | chr4:g.54727419_54727439del21 | c.1654_1674del21 | p.P552_W558delPMYEVQW | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54727422_54727442del21 | c.1654_1674del21 | p.M552_K558delMYEVQWK | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54727422_54727442del21 | c.1654_1674del21 | p.M552_K558delMYEVQWK | RefSeq | GRCh38/hg38 |
XM_017008179.1 | chr4:g.54727432_54727452del21 | c.1655_1675del21 | p.V552_E558delVQWKVVE | RefSeq | GRCh38/hg38 |
NM_001385284.1 | chr4:g.54727419_54727439del21 | c.1654_1674del21 | p.P552_W558delPMYEVQW | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727422_54727442del21 | c.1654_1674del21 | p.M552_K558delMYEVQWK | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT M552_K558del | gastrointestinal stromal tumor | predicted - resistant | Ponatinib | Case Reports/Case Series | Actionable | In a clinical study, a GIST patient harboring KIT M552_K558del, resistant to multiple tyrosine kinase inhibitors, demonstrated resistance to Iclusig (ponatinib) treatment as indicated by disease progression after 4 weeks of treatment (PMID: 25239608). | 25239608 |